CSIMarket Company Name, Ticker, Suppliers, else..
 
Cnbx Pharmaceuticals Inc   (CNBK)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Cnbx Pharmaceuticals Inc
Cnbx Pharmaceuticals Inc is a pharmaceutical company that specializes in the research, development, and commercialization of innovative therapeutic products. They focus on developing treatments for various conditions and diseases, including cancer, inflammatory diseases, and neurological disorders. The company combines advanced technology, scientific expertise, and strategic collaborations to create novel drug candidates for improved patient outcomes. Cnbx Pharmaceuticals Inc is committed to making a positive impact in the healthcare industry by delivering effective and safe therapies to patients globally.


   Company Address: #3 Bethesda Metro Center Bethesda 20814 MD
   Company Phone Number: 424-2429   Stock Exchange / Ticker: CNBK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cnbx Pharmaceuticals Inc

Cnbx Pharmaceuticals Inc Reports Zero Revenue in Latest Financial Period, Sparks Interest Among Investors

Cnbx Pharmaceuticals Inc, a pharmaceutical company, recently reported its financial results for the period ending May 31, 2024. The company recorded a decline in earnings per share (EPS) compared to the previous year, with the current EPS reaching $0.00 per share compared to -$0.02 per share in the prior year. This indicates that the company has managed to maintain its profitability and avoid losses.
In terms of revenue, Cnbx Pharmaceuticals Inc saw no change from the previous year, with the figure remaining at $0.00 million. This is a significant drop from the $0.31 million recorded in the comparable reporting period a year ago. Additionally, the revenue for the most recent reporting period was $0.04 million, indicating a sequential decrease.
Cnbx Pharmaceuticals Inc

Cnbx Pharmaceuticals Inc Surges Ahead with Revenue Growth of $0.040637 Million

Cnbx Pharmaceuticals Inc Sets Positive Financial Trend with Revenue Growth
In an impressive financial turnaround, Cnbx Pharmaceuticals Inc announced a revenue of $0.040637 million for the financial period ending on February 29, 2024. This remarkable figure reflects a substantial increase from the corresponding quarter a year ago, signaling positive momentum for the pharmaceutical company.
Even more notable is the company's net shortfall of only $-0.325 million, a stark contrast to the $-2.624 million deficit reported in the same quarter last year. This astonishing reduction in losses underlines Cnbx Pharmaceuticals Inc's commitment to improving operational efficiency and financial stability.
Cnbx Pharmaceuticals Inc

Cnbx Pharmaceuticals Inc Reports Impressive Revenue Growth of $0.089437 Million in Recent Fiscal Period



Cnbx Pharmaceuticals Inc has recently reported its financial results for the most recent fiscal period, revealing positive signs of growth and improvement. Despite a net deficit, the company's revenue has showcased a substantial increase compared to the same quarter of the previous year. This article explores the financial figures, highlights the positive aspects of the recent report, and discusses how these results have impacted Cnbx Pharmaceuticals Inc.
Impressive Revenue Growth
In the most recent fiscal period, Cnbx Pharmaceuticals Inc has reported a solid revenue figure of $0.089437 million. This marks a significant improvement compared to the comparable quarter a year ago when the revenue stood at $0.000 million. The remarkable growth of revenue demonstrates Cnbx Pharmaceuticals Inc's ability to effectively generate sales and capture a larger market share.
Cnbx Pharmaceuticals Inc

Cnbx Pharmaceuticals Inc. Surpasses Expectations with $0.1 Million in Fourth Quarter Revenue, Defying Industry Challenges



Cnbx Pharmaceuticals Inc, a leading player in the pharmaceutical industry, recently released its financial results for the fiscal year ending August 31, 2023. While the company reported a net deficit larger than the previous year, the overall picture remains bullish, backed by steady revenue growth and a commitment to balanced financials. In this article, we will analyze the results and discuss how they have impacted the company's growth trajectory.
Strong Revenue Growth Amidst Challenging Times:
Despite the ongoing challenges faced by the pharmaceutical industry, Cnbx Pharmaceuticals Inc. achieved considerable revenue of $0.1 million during the fiscal period ending August 31, 2023. This represents a substantial increase from the previous financial year, indicating that the company's strategic initiatives are driving revenue growth.
Cnbx Pharmaceuticals Inc

CNBX Pharmaceuticals Inc Reports Revenue of $0.310165 Million for the Quarter Ending May 31, 2023

CNBK, a pharmaceutical company, recently revealed their financial results for the period spanning from March to May 31, 2023. During this time, the company reported a revenue of $0.310165 million. This marks an improvement compared to the same quarter in the previous year when they had a deficit of $0.682 million.
The positive financial performance is an encouraging sign for CNBK, as they were able to significantly reduce their net shortfall from the previous year. In the March to May 31, 2023, span, the company reported a net shortfall of $-0.155 million, a significant improvement from the deficit of $-0.682 million in the similar quarter a year ago.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com